Clinical trials: Clostridium Difficile Infection Recurrence
Clostridium Difficile Infection
A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection
This study is a two-arm, interventional, prospective, open-label, multi-center clinical trial with randomized and non-randomized study groups to evaluate the safety and effectiveness of faecal microbiota transplantation (FMT) for…
- Trial name
- FMTREAT (NCT03053505)
- Testing
- faecal human microbiota transplant (FMT), Vancomycin or Fidaxomicin
- Where
- 3 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Sejtterapia Kozpont Kft.
Clostridium Difficile Infection
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of…
- Trial name
- NCT02830542
- Testing
- SER-262
- Where
- 22 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seres Therapeutics, Inc.
C.Difficile Diarrhea
Clostridium Difficile Infection (CDI) in Hematologic Patients.
The microbiology department prospectively generates a data base of all episodes of Clostridium difficile infection (CDI) in the institution, the investigators will analyse the evolution of the episodes and the incidence per…
- Trial name
- NCT03964844
- Testing
- No intervention
- Where
- Spain
- Volunteers
- 450 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Clostridium Difficile Infection Recurrence
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Single-arm trial to evaluate the safety and efficacy of ACX-362E [ibezapolstat] in patients with recurrent C. difficile infection (CDI).
- Trial name
- NCT07513285
- Testing
- Ibezapolstat
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Acurx Pharmaceuticals Inc.
Clostridium Infections, Clostridioides Difficile
Bezlotoxumab Versus FMT for Multiple Recurrent CDI
The objective of this trial is to investigate whether a treatment strategy offering bezlotoxumab before FMT in patients suffering from multiple recurrent CDI results in equal efficacy compared with a treatment strategy with…
- Conditions
- Clostridium Infections, Clostridioides Difficile, Enterocolitis, Pseudomembranous
- Trial name
- BSTEP (NCT05077085)
- Testing
- Bezlotoxumab, Fecal Microbiota Transplantation (FMT), Vancomycin oral
- Where
- 4 sites in Netherlands
- Sponsor
- Leiden University Medical Center
Clostridioides Difficile Infection Recurrence, FMT
FMT Capsules for rCDI
Double blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.
- Trial name
- FMT CAP CDI (NCT07458984)
- Testing
- Healthy donor stool
- Where
- Finland
- Volunteers
- 76 people
- Sponsor
- Helsinki University Central Hospital
Clostridium Difficile
Fresh Versus Frozen Stool for Fecal Transplant in Children
The primary goal of this study will be to assess whether stool collected and frozen from anonymous screened unrelated donors can be as effective as stool freshly collected from recipient's parents when used in Fecal Microbial…
- Trial name
- NCT02423967
- Testing
- Transplant uses frozen anonymous stool, Transplant uses fresh familial stool
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Clostridium Difficile Infection
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
The study aims to describe the characteristics and the methods of management and follow-up of patients treated with fidaxomicin for Clostridium difficile infection (CDI).
- Trial name
- DAFNE (NCT02214771)
- Testing
- Fidaxomicin, Treatment for CDI other than fidaxomicin Type
- Where
- 24 sites in France
- Volunteers
- 296 people
- Sponsor
- Astellas Pharma S.A.S.
Clostridium Difficile Infection Recurrence, Ulcerative Colitis (UC)
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics
This is a large-scale observational study aiming to evaluate the long-term effectiveness and safety of Fecal Microbiota Transplantation (FMT).
- Conditions
- Clostridium Difficile Infection Recurrence, Ulcerative Colitis (UC), Crohn Disease (CD), Irritable Bowel Syndrome (IBS)
- Trial name
- NCT07261826
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Chen QiYi
Clostridium Enterocolitis, Pseudomembranous Colitis
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
The purpose of this study is to compare the outcome of treatment with nitazoxanide vs. vancomycin for diarrheal disease due to Clostridium difficile in patients who have failed previous treatment with metronidazole.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304889
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridioides Difficile Infection Recurrence
Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation
Clostridioides difficile infection (CDI) is the most common cause of nosocomial diarrhea, and the most common health care-associated infectious disease in the United States, accounting for 15% of overall infections, nearly 30.000…
- Trial name
- NCT05739825
- Testing
- FMT from healthy donors
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Clostridium Difficile Infection
Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection
This is a medical research study designed to look at the safety and efficacy of 30-day course of fidaxomicin for treatment of recurrent CDI (Clostridium difficile Infection).
- Trial name
- NCT02395848
- Testing
- Fidaxomicin
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- McMaster University
Clostridium Difficile Infection Recurrence
Bezlotoxumab Efficacy and Tolerability in Cancer Patient
Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.
- Trial name
- NCT04415918
- Testing
- Bezlotoxumab Injection
- Volunteers
- 132 people
- Sponsor
- The Cooper Health System
Clostridium Difficile
Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection
In the recent past, a deep change in the epidemiology of C. difficile infection has occurred, with a rise in its frequency, severity, and mortality.
- Trial name
- NCT02148601
- Testing
- Fecal Microbiota Transplantation, Standard Antibiotic Therapy, Vancomycin (before randomization)
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Catholic University of the Sacred Heart
Clostridium Difficile Infection
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
The first line therapy for an initial episode of CDI (Clostridium difficile infection) is 10-14 days of oral vancomycin which is now recommended over metronidazole in the 2018 guidelines from the Association of Medical…
- Trial name
- TAPER-V (NCT04138706)
- Testing
- Vancomycin
- Where
- 12 sites in Canada
- Volunteers
- 263 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Clostridium Difficile Infection
Treatment of Recurrent Clostridium Difficile Infection With RBX7455
The purpose of this study is to demonstrate the efficacy and safety of RBX7455 for the treatment of recurrent CDI in subjects who have had at least one recurrence after a primary episode (i.e., at least two episodes) and have…
- Trial name
- NCT02981316
- Testing
- RBX7455
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical…
- Trial name
- NCT04317963
- Testing
- Bezlotoxumab, Standard CDI treatment
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Illinois at Chicago
Clostridium Difficile Colitis
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
The incidence of C. difficile infection (CDI) has alarmingly increased over the past several years and the affected population has expanded to include those previously at low risk, such as children.
- Trial name
- NCT01972334
- Testing
- FMT
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Clostridia Difficile Colitis, Clostridium Difficile Diarrhea
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection
Fecal microbiota transplantation (FMT) is a treatment that restores the balance of gut bacteria and is the most effective treatment for patients who suffer from recurrent Clostridioides difficile infection (CDI) brought on by…
- Trial name
- NCT03806803
- Testing
- Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate
- Where
- 5 sites in Canada
- Volunteers
- 138 people
- Sponsor
- University of Alberta
Clostridium Difficile Infections
Molecular Epidemiology of Clostridium Difficile Infections in Children
Objectives: 1. Describe the molecular epidemiology of Clostridium Difficile infection in children in the Chicago area. 2. Determine the clinical spectrum and risk factors for Clostridium Difficile infection secondary to…
- Trial name
- NCT01957761
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago